Articles published by Omeros Corporation

< Previous 1 2 3 Next >

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

November 02, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

October 19, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

October 16, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports Second Quarter 2023 Financial Results

August 09, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023

August 04, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Announces Webcast Details for Annual Meeting of Shareholders

June 21, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

June 12, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

June 01, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports First Quarter 2023 Financial Results

May 09, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

May 04, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

April 25, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program

April 10, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

March 13, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank

March 10, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023

March 07, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

February 06, 2023

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports Third Quarter 2022 Financial Results

November 09, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

November 08, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

November 04, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

November 03, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

October 03, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

September 15, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

August 17, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports Second Quarter 2022 Financial Results

August 09, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022

August 04, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

July 29, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Announces Webcast Details for Annual Meeting of Shareholders

June 15, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation Reports First Quarter 2022 Financial Results

May 10, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022

May 04, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

April 20, 2022

From Omeros Corporation

Via Business Wire

Tickers OMER

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.